+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 57 Actively Recruiting clinical trials

L

Actively Recruiting

This research aims to evaluate the long-term safety and efficacy of APG777 in adults with moderate-to-severe atopic dermatitis who have already completed treatment in a prior APG777 study. The study is a multicenter, double-blind, phase 2 extension designed for participants who, according to the investigator, could benefit from continued APG777 treatment. The study consists of three periods a Screening Visit coinciding with the last visit of the parent studys Maintenance Period an Extended Treatment Period where participants maintain their APG777 dose from the previous study or receive open-label APG777 if they did not meet certain response criteria and a Post-treatment Follow-up Period. Participants receive APG777 as subcutaneous injections every 12 or 24 weeks, depending on their previous dosing regimen or study arm assignment. During the study, participants will have assessments for safety and efficacy, including monitoring treatment-emergent adverse events for up to 3 years. Researchers will also track improvements in eczema severity, itch symptoms, use of rescue therapy, and serum drug concentrations over an average of 2 years during the Extended Treatment Period. Participation may last up to 3 years, including follow-up to observe long-term outcomes.

Age: 18Years +All GendersPhase 2
80 locations
E

Actively Recruiting

Researchers are evaluating the effects of camoteskimab in adults aged 18 to 65 with moderate-to-severe atopic dermatitis. This phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of camoteskimab compared to placebo. Participants include those who are treatment-naive or have had an inadequate response to previous biologic therapies. The study has two parts Part 1 is a 24-week placebo-controlled period where participants are randomly assigned to one of three camoteskimab dose levels or placebo, all administered by subcutaneous injection. In Part 2, an extension period, all participants receive camoteskimab. This design allows comparison of different dose levels and monitoring of long-term treatment effects. Participants will be assessed regularly throughout the study with measures including the Eczema Area and Severity Index EASI, Investigator Global Assessment IGA, and peak pruritus numerical rating scale PP-NRS. Safety and efficacy will be monitored through these assessments over 24 weeks and beyond. The study includes signing informed consent and adherence tracking, with the primary outcome focused on percentage change in EASI score from baseline to Week 24.

Age: 18Years - 65YearsAll GendersPhase 2
85 locations
E

Actively Recruiting

Researchers are evaluating the safety and efficacy of GIA632 in adults aged 18 to 99 years with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled Phase 2b study aims to identify the optimal dose of GIA632 to be further studied in a Phase 3 program. The study also includes an extension period to assess longer-term safety and effectiveness. Participants will be randomly assigned to one of several groups receiving either GIA632 or a placebo during a 48-week core treatment period. The study will measure the dose-response relationship of GIA632 and compare its effects with placebo. The extension phase will further evaluate the safety and efficacy over a longer term. During the study, participants will have regular assessments including measurement of facial and total body vitiligo area using the Vitiligo Area Scoring Index VASI at baseline and multiple time points up to 48 weeks. Researchers will also track improvements using the Vitiligo Noticeability Scale. Safety and treatment response will be monitored throughout the study period, which lasts up to approximately four years including follow-up.

Age: 18Years - 99YearsAll GendersPhase 2
83 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
S

Actively Recruiting

Researchers are studying patients with hypercholesterolaemia who either have a history of clinical atherosclerotic cardiovascular disease ASCVD or are at increased risk for a first ASCVD event. The trial aims to evaluate the effect on low-density lipoprotein-cholesterol LDL-C and the safety and tolerability of a fixed dose combination FDC of laroprovstatrosuvastatin compared to rosuvastatin alone. This is a Phase III randomized, double-blind, parallel-group study sponsored by AstraZeneca. Participants will be assigned to one of several groups receiving daily oral doses of laroprovstatrosuvastatin or rosuvastatin alone at different dose levels. Each laroprovstatrosuvastatin dose group is paired with a matching placebo to maintain blinding. The treatments are given daily over a period of 8 weeks to assess their effects on cholesterol levels. During the study, participants will undergo assessments to measure changes in LDL-C as the primary outcome at 8 weeks, along with secondary measures including Apo B, non-HDL cholesterol, and total cholesterol. Safety and tolerability will also be monitored throughout the treatment. Participants will have scheduled visits during the treatment period to ensure adherence and collect data, with the overall study completion projected by May 2027.

Age: 18Years - 130YearsAll GendersPhase 3
45 locations
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
B

Actively Recruiting

Researchers are conducting the BALANCE platform trial to study different treatment strategies for Gram-negative bloodstream infections GN BSIs. This adaptive trial addresses important questions about managing these infections, which have high risks and are complicated by increasing antibiotic resistance. The trial builds on previous research and aims to improve treatment approaches and patient outcomes while addressing antimicrobial resistance challenges. Participants in the trial receive various treatments depending on the domain they are assigned to. These include strategies such as antibiotic de-escalation or continuation, use of oral beta-lactams versus non-beta-lactams, decisions about replacing or retaining central vascular catheters, comparison of cephalosporins versus carbapenems for certain bacteria, and whether to perform routine follow-up blood cultures. The trial is open-label and embedded in routine hospital care, with an adaptive design that allows adding or removing treatment domains over time. During the study, participants undergo regular evaluations including monitoring for death, reinfection, readmission, and development of antimicrobial resistance over 90 days. The main measurement used is the Desirability of Outcome Ranking DOOR scale. Interim analyses occur frequently to assess results and determine continuation. Participation includes hospital admission, treatment under routine care with study interventions, and follow-up for outcome assessments. The study is planned to continue until April 2028 and enrolls patients from newborns to elderly adults.

Age: 0Years - 130YearsAll GendersPhase Not Applicable
39 locations
O

Actively Recruiting

Researchers are conducting a noninterventional, prospective observational study in Canada to monitor participants with Alzheimers Disease who are treated with LEQEMBI during routine clinical practice. The study aims to describe the occurrence and severity of known side effects, including brain imaging abnormalities and intracerebral hemorrhages, and analyze these according to genetic factors, other medications, and baseline brain scans. Additionally, the study will observe the progression of Alzheimers Disease and identify any previously unknown side effects related to LEQEMBI. Participants in this registry study are those prescribed LEQEMBI and will be observed without any experimental treatment or intervention. The study collects data on drug use, adverse events, disease progression, and the effectiveness of safety measures over a period of up to three years. There is no active treatment administered by the study, and information is gathered during routine medical care. During the study, participants will have their health monitored through regular clinical practice assessments. Researchers will track side effects, disease progression, treatment duration, and drug utilization. Data on serious adverse reactions, treatment discontinuations, and deaths within 30 days of stopping LEQEMBI will also be collected. The study will last up to three years with ongoing observation to evaluate the safety and outcomes associated with LEQEMBI use.

All AgesAll Genders
17 locations
S

Actively Recruiting

Researchers are evaluating how CDR132L, a potential new medicine, affects the structure and function of the heart in people living with heart failure. The study focuses on individuals with preserved ejection fraction and left ventricular hypertrophy. It is a phase 2, randomized, double-blind, placebo-controlled trial aimed at assessing the safety and efficacy of CDR132L on reversing cardiac remodeling. Participants will be randomly assigned to receive one of three different doses of CDR132L or a placebo. All treatments are given as intravenous infusions once every 4 weeks for 48 weeks. Throughout the study, participants will continue their individually tailored guideline-directed standard care therapy for heart failure. The trial duration is about 60 weeks. During the study, participants will undergo various assessments, including measuring changes in microRNA-132 levels as the primary outcome at 24 weeks. Secondary outcomes include changes in heart structure measured by cardiac magnetic resonance imaging and blood biomarkers, as well as monitoring adverse events up to 60 weeks. Participants will receive regular infusions and attend scheduled visits for monitoring and safety evaluations.

Age: 40Years - 84YearsAll GendersPhase 2
118 locations
S

Actively Recruiting

Researchers are evaluating how well once-weekly insulin icodec maintains blood sugar levels compared to daily basal insulin injections in adults with type 2 diabetes. The study focuses on people who need to start basal insulin treatment after using other glucose-lowering medications. This phase 4 trial aims to assess insulin icodecs effectiveness in real-world clinical practice over about 13 months. Participants will be randomly assigned to receive either weekly subcutaneous injections of insulin icodec or daily subcutaneous injections of basal insulin analogues such as insulin glargine, detemir, or degludec. The study compares these two insulin regimens as part of standard type 2 diabetes care. Treatment continues during the 52-week period to monitor blood sugar control and treatment satisfaction. Throughout the study, participants will undergo assessments including measuring changes in glycated hemoglobin HbA1c from baseline to week 52. They will also complete questionnaires on treatment adherence, satisfaction, and burden, and researchers will track severe hypoglycemia episodes and insulin doses. The trial spans about 13 months, providing thorough monitoring of treatment impact and safety in daily clinical use.

Age: 18Years +All GendersPhase 4
75 locations

1-10 of 57

1